Bone was the most representative site of metastases (20, 69%). During the follow-up period locoregional recurrence occurred in 1 (1.5%) and distant metastasis in 15 (22%) men, respectively. Triple negative breast cancer were diagnosed in 4 (6%) pts. Estrogen receptor, PR, and human epidermal growth factor receptor 2/neu positive were seen in 62 (92.5%), 60 (89.5%), and 15 (22%) patients, respectively. In radically treated 44 men, neoadjuvant chemotherapy was given to 20 (29%) patients with pCR in 1 (1.5%) and neoadjuvant hormonotherapy (tamoxifen) in 5 (7.5%) of pts.
Majority (59, 88%) of men had invasive ductal carcinoma histology. Early, locally advanced, and metastatic disease were seen in 44 (65%), 9 (14%), and 14 (21%) men, respectively. Family history was present in 15 (22%) men and in as 17 pts (25%) other cancer were diagnosed (prostate cancer, melanoma, Hodgkin lymphoma, NET, thyroid cancer). Patients with a primary diagnosis of breast cancer were identified in the our database.Results: The median age was 65 years (range 22-93 years). The understanding of biology, clinical presentation, genetics, and management of MBC is evolving but there still remains a large knowledge gap due to the rarity of this disease.Patients and methods: The aim of this retrospective study is to analyze the epidemiologic, clinical and therapeutic problems with this disease and to compare some cancer aspects between male and female in 67 cases collected at Maria Sklodowska Curie National Research Institute of Oncology in Warsaw between 05.2011 and 02.2021. Prospective data in the management of male breast cancer are lacking and majority of treatment strategies are adopted from the established guidelines for breast cancer in women. Male breast cancer is not very well understood. Background: Male breast cancer is a rare disease accounting for less than 1% of all breast cancer diagnoses worldwide.
0 kommentar(er)
